{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:28:10Z","timestamp":1791584890154,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.ejca.2017.02.030","type":"journal-article","created":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T11:07:27Z","timestamp":1494500847000},"page":"228-236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"special_numbering":"C","title":["Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer"],"prefix":"10.1016","volume":"81","author":[{"given":"Andrew J.","family":"Armstrong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Halabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Healy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshi J.","family":"Alumkal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Winters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Kephart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhonda L.","family":"Bitting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carey","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen F.","family":"Soleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz M.","family":"Beer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Slottke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Mundy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan Y.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2017.02.030_bib1","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.02.030_bib2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.02.030_bib3","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.02.030_bib4","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2017.02.030_bib5","first-page":"LBA4512","volume":"vol. 30","author":"Parker","year":"2012"},{"key":"10.1016\/j.ejca.2017.02.030_bib6","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.02.030_bib7","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2017.02.030_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","article-title":"Integrative genomic profiling of human prostate cancer","volume":"18","author":"Taylor","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2017.02.030_bib9","doi-asserted-by":"crossref","first-page":"5692","DOI":"10.1158\/1078-0432.CCR-10-1601","article-title":"Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma","volume":"16","author":"Dubrovska","year":"2010","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ejca.2017.02.030_bib10","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1073\/pnas.0810956106","article-title":"The role of PTEN\/Akt\/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations","volume":"106","author":"Dubrovska","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejca.2017.02.030_bib11","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1158\/0008-5472.CAN-09-2525","article-title":"Isoform-specific phosphoinositide 3-kinase inhibitors exert\u00a0distinct effects in solid tumors","volume":"70","author":"Edgar","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2017.02.030_bib12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ccell.2014.11.008","article-title":"Feedback suppression of PI3Kalpha signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kbeta","volume":"27","author":"Schwartz","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2017.02.030_bib13","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1158\/1078-0432.CCR-10-0124","article-title":"A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer","volume":"16","author":"Armstrong","year":"2010","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ejca.2017.02.030_bib14","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.clgc.2013.05.007","article-title":"A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer","volume":"11","author":"Armstrong","year":"2013","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ejca.2017.02.030_bib15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.clgc.2014.08.007","article-title":"A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer","volume":"13","author":"Courtney","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ejca.2017.02.030_bib16","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1002\/cncr.29578","article-title":"Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: phase 1\/2 results and signaling pathway implications","volume":"121","author":"Rathkopf","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2017.02.030_bib17","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.eururo.2013.03.040","article-title":"Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08\/08)","volume":"64","author":"Templeton","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2017.02.030_bib18","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1158\/1535-7163.MCT-11-0474","article-title":"Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor","volume":"11","author":"Maira","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2017.02.030_bib19","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.2011.36.1360","article-title":"Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors","volume":"30","author":"Bendell","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.02.030_bib20","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ccr.2011.04.008","article-title":"Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer","volume":"19","author":"Carver","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2017.02.030_bib21","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ccr.2011.05.006","article-title":"Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth","volume":"19","author":"Mulholland","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2017.02.030_bib22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2017.02.030_bib23","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.02.030_bib24","series-title":"2008 Genitourinary Cancers Symposium","article-title":"A phase II study of RAD001 in men with hormone-refractory metastatic prostate cancer (HRPC)","author":"George DAAC","year":"2008"},{"key":"10.1016\/j.ejca.2017.02.030_bib25","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.02.030_bib26","doi-asserted-by":"crossref","first-page":"ra116","DOI":"10.1126\/scisignal.aad5111","article-title":"Cell type-specific abundance of 4EBP1 primes prostate cancer sensitivity or resistance to PI3K pathway inhibitors","volume":"8","author":"Hsieh","year":"2015","journal-title":"Sci Signal"},{"key":"10.1016\/j.ejca.2017.02.030_bib27","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1158\/2159-8290.CD-13-0611","article-title":"Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling","volume":"4","author":"Will","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2017.02.030_bib28","doi-asserted-by":"crossref","first-page":"8638","DOI":"10.1073\/pnas.1500722112","article-title":"PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion","volume":"112","author":"Caino","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejca.2017.02.030_bib29","first-page":"107","article-title":"Adaptive mitochondrial reprogramming and resistance to PI3K therapy","author":"Ghosh","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2017.02.030_bib30","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1111\/j.1464-410X.2012.11456.x","article-title":"Phase II trial of RAD001 and bicalutamide for\u00a0castration-resistant prostate cancer","volume":"110","author":"Nakabayashi","year":"2012","journal-title":"BJU Int"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917308924?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917308924?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T19:52:50Z","timestamp":1535831570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917308924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":30,"alternative-id":["S0959804917308924"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.02.030","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.02.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}